| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, P Tomczak, MD Michaelson, RM Bukowski, O Rixe, ... New England Journal of Medicine 356 (2), 115-124, 2007 | 7332 | 2007 |
| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 6298 | 2015 |
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma G Hudes, M Carducci, P Tomczak, J Dutcher, R Figlin, A Kapoor, ... New England Journal of Medicine 356 (22), 2271-2281, 2007 | 4706 | 2007 |
| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4496 | 2018 |
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... The Lancet 372 (9637), 449-456, 2008 | 3788 | 2008 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3506 | 2019 |
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma RJ Motzer, TE Hutson, P Tomczak, MD Michaelson, RM Bukowski, ... Journal of clinical oncology 27 (22), 3584-3590, 2009 | 2835 | 2009 |
| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2457 | 2019 |
| Renal-cell carcinoma RJ Motzer, NH Bander, DM Nanus New England Journal of Medicine 335 (12), 865-875, 1996 | 2345 | 1996 |
| Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma RJ Motzer, M Mazumdar, J Bacik, W Berg, A Amsterdam, J Ferrara Journal of clinical oncology 17 (8), 2530-2530, 1999 | 2271 | 1999 |
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial BI Rini, B Escudier, P Tomczak, A Kaprin, C Szczylik, TE Hutson, ... The Lancet 378 (9807), 1931-1939, 2011 | 2220 | 2011 |
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ... New England Journal of Medicine 369 (8), 722-731, 2013 | 2192 | 2013 |
| Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal … RJ Motzer, MD Michaelson, BG Redman, GR Hudes, G Wilding, RA Figlin, ... Journal of Clinical Oncology 24 (1), 16-24, 2006 | 2173 | 2006 |
| Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma RJ Motzer, J Bacik, BA Murphy, P Russo, M Mazumdar Journal of clinical oncology 20 (1), 289-296, 2002 | 2108 | 2002 |
| Sunitinib in patients with metastatic renal cell carcinoma RJ Motzer, BI Rini, RM Bukowski, BD Curti, DJ George, GR Hudes, ... Jama 295 (21), 2516-2524, 2006 | 1641 | 2006 |
| Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... Cancer 116 (18), 4256-4265, 2010 | 1542 | 2010 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1508 | 2021 |
| Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ... New England Journal of Medicine 384 (9), 829-841, 2021 | 1480 | 2021 |
| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1345 | 2015 |
| Testicular germ-cell cancer GJ Bosl, RJ Motzer New England Journal of Medicine 337 (4), 242-254, 1997 | 1243 | 1997 |
